GCTK (GlucoTrack) 12-1 Month Momentum %: 23.48% (As of Sep. 04, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

GCTK GlucoTrack Inc GCTK
27 GF Score
Price $3.32
! 2 Warning Signs
View Full Analysis

What is GlucoTrack 12-1 Month Momentum %?

GlucoTrack GCTK -5.82% 27 12-1 Month Momentum % is 23.48% as of Sep. 04, 2026. GuruFocus rates GCTK with a GF Score™ of 27/100. The stock has 2 warning signs investors should review. Among 825 Medical Devices & Instruments companies, GlucoTrack ranks better than 88.12% on this metric.

12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2026-09-04), GlucoTrack's 12-1 Month Momentum % is 23.48%.

The industry rank for GlucoTrack's 12-1 Month Momentum % or its related term are showing as below:

GCTK's 12-1 Month Momentum % is ranked better than
88.12% of 825 companies
in the Medical Devices & Instruments industry
Industry Median: -19.24 vs GCTK: 23.48

GlucoTrack  (NAS:GCTK) 12-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

GlucoTrack 12-1 Month Momentum % Related Terms

GCTK vs TNON, RMSL, FEED: 12-1 Month Momentum % Comparison

For the Medical Devices subindustry, GlucoTrack's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

GlucoTrack 12-1 Month Momentum % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, GlucoTrack's 12-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where GlucoTrack's 12-1 Month Momentum % falls into.


GCTK
27GF Score
GlucoTrack Inc GCTK
12-1 Month Momentum % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

GlucoTrack  (NAS:GCTK) 12-1 Month Momentum % Calculation

12-1 Month Momentum % is calculated as following:

12-1 Month Momentum %=( Price 1-month ago / Price 12-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 12-1 Month Momentum % →
What does a 12-1 Month Momentum % of 23.48% mean?
GlucoTrack (GCTK) has a 12-1 Month Momentum % of 23.48% as of Sep. 04, 2026. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on GlucoTrack and its competitors. According to the industry distribution chart, GlucoTrack ranks #98 out of 825 companies in the Medical Devices & Instruments industry, placing it in the top 11.9%.
Is GlucoTrack's 12-1 Month Momentum % too high?
GlucoTrack's current 12-1 Month Momentum % is 23.48%. Based on the distribution chart, GlucoTrack ranks #98 out of 825 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, GlucoTrack has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does GlucoTrack's 12-1 Month Momentum % compare to TNON and RMSL?
According to the Medical Devices & Instruments industry distribution chart, GlucoTrack ranks #98 out of 825 companies for 12-1 Month Momentum %. This places GlucoTrack in the top 12% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 12-1 Month Momentum % for a Medical Devices & Instruments company?
A good 12-1 Month Momentum % depends on the Medical Devices & Instruments industry context. However, 12-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 12-1 Month Momentum % mean?
A high 12-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on GlucoTrack and its competitors. GlucoTrack's current 12-1 Month Momentum % is 23.48%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GlucoTrack stock overvalued right now?
GlucoTrack (GCTK) has a current 12-1 Month Momentum % of 23.48%. The current 12-1 Month Momentum % is 23.48%. GlucoTrack's overall GF Score™ is 27/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 12-1 Month Momentum % calculated?
12-1 Month Momentum % is calculated from a company's financial statements. For GlucoTrack (GCTK), the current 12-1 Month Momentum % is 23.48% as of Sep. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

GlucoTrack Business Description

Address 301 Route 17 North, Suite 800, Rutherford, NJ, USA, 07070
GlucoTrack Inc is a medical device company focused on the development of an implantable continuous blood glucose monitor (CBGM) for patients with Type 1 and Type 2 diabetes. The company is developing its Glucotrack CBGM system to provide continuous glucose monitoring using implantable sensor technology and is advancing the product through clinical studies and regulatory processes.
27GF Score

Get the complete analysis for GCTK

12-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.32
Price